Australian-based reproductive biotechnology company Memphasys Limited (ASX: MEM) has named acting Chief Executive Officer and Executive Director Dr David Ali as the full time CEO effective 1st July 2024
Dr Ali is a highly qualified senior executive with more than 40 years’ experience in medical management, business development, sales and marketing for pharmaceutical, medical device and diagnostic companies in human and animal reproduction.
“I am very pleased to formally welcome Dr Ali to the position of Chief Executive Officer of Memphasys on a permanent full-time basis, where he will continue to lead the management team to build a commercial sales pipeline for its Felix System whilst also developing a suite of further growth initiatives for human and animal use,” Memphasys Chairman Robert Cooke said.
“The appointment reflects the Board’s immense confidence in David who joined the company in March 2023 and has served as Acting CEO since November 2023.
“During his tenure as acting CEO, he has overseen multiple distribution agreements in international marketplaces, accelerated sales activity in Japan as well as continued the development of Memphasys’ other technologies. With this extensive experience, David is exceptionally well equipped to lead the company in its next chapter of growth”
